

1 **Autoantibodies against nephrin elucidate a novel autoimmune phenomenon in proteinuric**
2 **kidney disease**

3

4 **Authors**

5 Andrew J.B. Watts^{1,2*}, Keith H. Keller^{1*}, Gabriel Lerner^{3,4}, Ivy Rosales⁵, A. Bernard Collins⁵,
6 Miroslav Sekulic^{1,6}, Sushrut S. Waikar^{2,4}, Anil Chandraker², Leonardo V. Riella², Mariam P.
7 Alexander⁷, Jonathan P. Troost⁸, Junbo Chen³, Damian Fermin⁹, Jennifer Lai Yee⁹, Matthew
8 Sampson^{10,11}, Laurence H. Beck, Jr.⁴, Joel M. Henderson³, Anna Greka^{2,11}, Helmut G. Rennke¹,
9 and Astrid Weins^{1,2,†}

10

11 ¹Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School,
12 Boston, MA

13 ²Renal Division, Department of Medicine, Brigham and Women's Hospital, and Harvard
14 Medical School, Boston, MA

15 ³Department of Pathology, Boston Medical Center and Boston University, Boston, MA

16 ⁴Section of Nephrology, Department of Medicine, Boston Medical Center and Boston
17 University, Boston, MA

18 ⁵Department of Pathology, Massachusetts General Hospital, and Harvard Medical School,
19 Boston, MA

20 ⁶Department of Pathology and Cell Biology, Columbia University College of Physicians and
21 Surgeons

22 ⁷Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

23 ⁸Division of Nephrology, Department of Pediatrics, University of Michigan, Ann Arbor, MI

24 ⁹Division of Medicine, Department of Pediatrics, University of Michigan School of Medicine,
25 Ann Arbor, MI

26 ¹⁰Department of Medicine/Pediatric Nephrology, Boston Children's Hospital, and Harvard
27 Medical School, Boston, MA

28 ¹¹Broad Institute of MIT and Harvard, Cambridge, MA

29

30 *These authors contributed equally to this study.

31

32 †Corresponding author:

33

34 Astrid Weins, M.D., Ph.D.

35 Associate Pathologist, Department of Pathology, Brigham and Women's Hospital

36 Assistant Professor of Pathology, Harvard Medical School,

37 Cotran-3, Room AL380.B

38 75 Francis Street

39 Boston, MA 02115

40 Phone: 617-732-7671

41 aweins@bwh.harvard.edu

42

43

44

45

46

47

48

49 **Abstract**

50 Dysfunction of podocytes, cells critical for glomerular filtration, underlies proteinuria and kidney
51 failure. Genetic forms of proteinuric kidney disease can be caused by mutations in several
52 podocyte genes, including nephrin, a critical component of the kidney filter. In contrast, the
53 etiology of acquired acute-onset nephrotic syndrome has remained elusive. Here we identify
54 autoantibodies against nephrin in serum and glomeruli of a subset of adults and children with
55 non-congenital acute nephrotic syndrome. Our findings align with published experimental
56 animal studies and elucidate a novel autoimmune phenomenon in proteinuric kidney disease
57 interfering with glomerular filter integrity.

58

59 **Introduction**

60 Diffuse podocytopathy with minimal changes (Minimal Change Nephrotic Syndrome, MCNS) is
61 an important and common pathologic diagnosis in adults and children with nephrotic syndrome
62 (NS). It is characterized by minimal changes by light microscopy, but extensive injury to
63 glomerular podocytes with diffuse foot process effacement (FPE) and loss of slit diaphragms
64 (SD) by electron microscopy (EM) in the absence of electron dense deposits¹. The consequence
65 of these alterations is massive proteinuria secondary to failure of the glomerular filtration barrier
66 (GFB), whose integrity is critically dependent on the specialized junctional SD protein complex
67 linking the interdigitating podocyte foot processes.

68

69 Nephrin is an essential component of the SD^{2,3}, as illustrated by genetic mutations in nephrin,
70 that cause complete lack of cell surface localization, underlying Congenital Nephrotic Syndrome
71 of the Finnish Type (CNF)^{4,5}. In contrast to congenital NS with an established genetic basis, the
72 cause of non-congenital NS in both children and adults remains largely unknown. There is strong
73 evidence supporting immune dysregulation with a potential causative circulating factor, however
74 its identity has remained elusive^{6,7}. Glucocorticoids are effective at inducing remission, however
75 relapse, steroid dependence and intolerance are common, often requiring alternative
76 immunosuppressive agents⁸. In those patients with steroid dependent NS who progress to end
77 stage kidney disease (ESKD) and require kidney transplantation, the disease can promptly recur
78 in the allograft¹.

79

80 The recent discovery that anti-CD20 B-cell targeted therapies are effective in children with
81 frequently relapsing or steroid-dependent NS⁹⁻¹¹ and in adults¹² suggests a potential
82 autoantibody-mediated etiology. However, this possibility is hard to reconcile with the
83 traditional view of MCNS lacking IgG deposition on renal biopsy¹³. Whilst diffuse podocyte-
84 associated IgG is described in MCD, it is minimal compared to that seen in membranous
85 nephropathy (MN), and in the absence of deposits by EM is generally attributed to non-specific
86 protein resorption of little significance¹⁴.

87

88 Antibodies targeting this essential SD component nephrin have been shown to cause massive
89 proteinuria when administered in animal models¹⁵⁻¹⁷ and when they arise as alloantibodies
90 following kidney transplantation in children with CNF and complete nephrin deficiency¹⁸. In
91 both animal models^{15,16} and cultured podocytes^{7,19}, anti-nephin antibodies cause a redistribution

92 of nephrin that is identical to that observed in renal biopsies of patients with NS^{20,21}. This
93 redistribution of nephrin away from the SD has been proposed as a mechanism to explain the
94 proteinuria in these patients; however, the cause of this redistribution remains unknown.

95
96 Differing from classic immune complex deposition diseases such as membranous nephropathy,
97 the phenomenon of functional autoantibody-mediated disruption of a junctional adhesion
98 complex is well described for the blistering skin condition pemphigus²². In this disease,
99 autoantibodies directly bind desmogleins (dsg), a critical constituent of the desmosomal cell
100 adhesion complex, analogous to nephrin in the SD complex, and cause redistribution of dsg away
101 from the cell surface with consequent loss of desmosomal integrity and ultimately cell-cell
102 interactions²².

103
104 Taken together these observations led us to hypothesize that autoantibodies against nephrin may
105 underlie non-congenital MCNS by affecting the integrity of the SD complex.

106
107 **Results**

108 To first determine whether circulating autoantibodies against nephrin are detectable in the serum
109 of patients with biopsy proven MCD and no known genetic basis (lacking known pathogenic
110 variants in established Mendelian NS genes), we evaluated serum obtained from the Nephrotic
111 Syndrome Study Network (NEPTUNE) longitudinal cohort study²³ consisting of 41 (66%)
112 children and 21 (34%) adults (Table S1). We developed an indirect enzyme-linked
113 immunosorbent assay (ELISA) using a recombinant, affinity purified extracellular domain of
114 human nephrin (hNephrin_{G1059}) (Fig. S1) and established a threshold for anti-nephrin antibody

115 (ab) positivity, based on the maximum titer in a healthy control population (n=30) (Fig. 1a).
116 Evaluation of the earliest serum sample obtained during active disease (urine protein to
117 creatinine ratio, UPCR > 3g/g) revealed that 18 (29%) of 62 patients, with an equal number of
118 adults and children, were positive for autoantibodies against nephrin (Fig. 1a). Control sera from
119 53 (98%) of 54 patients who tested positive for anti-hPLA₂R antibodies, by clinically validated
120 ELISA and indirect immunofluorescence test (IIFT) assays, were negative for anti-nephrin ab
121 (Fig. 1a).

122
123 The patients' clinical characteristics (Table S2) and the median time from enrollment to
124 complete remission (CR) were similar between the anti-nephrin ab positive and negative groups
125 (4.4 months vs 5.4 months respectively; p=0.7288) (Fig. S2). However, the relapse-free period
126 was shorter for the anti-nephrin ab positive group compared with the ab negative group, although
127 this finding did not reach conventional levels of statistical significance (median time to relapse
128 6.0 months vs 21.57 months respectively; p=0.0945) (Fig. S2).

129
130 A subsequent serum sample was available during either complete (UPCR < 0.3 g/g) or partial
131 remission (>50% reduction in proteinuria) from 12 of the 18 anti-nephrin ab positive patients, in
132 whom we observed a complete absence or a significant reduction of nephrin autoantibodies
133 respectively (Fig. 1b, Figs. S3, S4). In keeping with the ELISA results, only serum obtained
134 during active disease or partial remission immunoprecipitated nephrin from healthy donor kidney
135 derived human glomerular extract (HGE), whereas serum obtained during complete remission
136 did not (Fig. 1c).

137

138 To further investigate a potential pathogenic role of these nephrin autoantibodies, we next sought
139 to establish whether they are present within kidneys of patients with MCD. One limitation of the
140 NEPTUNE cohort is that biopsy material from these patients was not available for further
141 evaluation and so we turned to our own institution and collaborators for biopsy and serum
142 samples.

143 For many years, we have observed a delicate punctate staining for IgG in a subset of patients
144 with MCD (MCD+) by routine immunofluorescence staining that is distinct from the background
145 (Fig. S5a). It is much more subtle when compared to the prominent IgG staining observed in MN
146 (Fig. S5a), and while this feature has been previously described¹⁴, its significance has not been
147 fully established. We therefore hypothesized that this subtle IgG may represent autoantibodies
148 targeting nephrin. To limit the possibility of staining artifacts, we routinely use a directly
149 conjugated FITC anti-human IgG F(ab)₂ ab which we have independently validated with a distinct
150 unconjugated anti-human IgG ab, an anti-light chain ab and isotype specific anti-IgG abs that all
151 show an identical staining pattern (Fig. S6). Importantly, we observe a complete lack of
152 concurrent glomerular albumin staining, indicating that this feature is IgG selective and does not
153 reflect non-specific protein resorption (Fig. S6).

154
155 We utilized confocal microscopy to further evaluate this punctate IgG in renal biopsies that were
156 received and processed by us over the last 3 years. We observed two predominant patterns of
157 IgG distribution: GBM-associated fine punctate or curvilinear structures and more apically
158 located punctate and vaguely vesicular clusters. These disparate staining patterns may reflect
159 different stages of antibody binding and/or redistribution. In all the MCD+ biopsies evaluated,
160 we observed specific co-localization of nephrin with the punctate IgG and not the background

161 (Fig 2a, Fig. S5b, Fig. S7) which was further corroborated in the control biopsies lacking this
162 punctate IgG (Fig. 2a, Fig. S5b). Antigen specificity was evidenced by a clear spatial association
163 of the IgG with the SD-associated nephrin but not with the podocyte foot process associated
164 synaptopodin by confocal microscopy (Fig. 2a,b, Fig. S5c) and by Super-Resolution Structured
165 Illumination Microscopy (SR-SIM) which achieves an even higher spatial resolution²⁴ (Fig. 2c,d,
166 Fig. S8). Furthermore, in those biopsies exhibiting the granular redistribution of nephrin away
167 from the SD, as previously described in MCD^{20,21}, the IgG did not co-localize with the three
168 intracellular podocyte specific proteins; synaptopodin (foot process associated), podocin (SD
169 associated) and WT1 (nuclear) (Fig. S9).

170
171 To confirm that MCD+ patients with punctate IgG on renal biopsy do indeed have circulating
172 autoantibodies against nephrin, we evaluated serum or plasma that was available specifically
173 during active disease for 9 of them. As expected, all 9 patients were serologically positive for
174 anti-nephrin antibodies by ELISA, in contrast to 12 control patients lacking punctate IgG on
175 renal biopsy, who were all serologically negative (Fig. 2e, Table S3). A follow-up serum or
176 plasma sample was available for 4 of the 9 MCD+ patients, which showed a significant reduction
177 in antibody titer concordant with treatment response (Fig. 2f, Fig. S10). These findings were
178 corroborated by IP (Fig. S11), and for all the patients in this study who were serologically
179 positive for circulating nephrin autoantibodies they did not cross react with PLA₂R (Fig. S12).

180
181 Finally, to highlight a potential role of pre-transplant nephrin autoantibodies in post-transplant
182 disease recurrence, which generally shows morphologic features indistinguishable from MCNS,
183 we identified a patient with childhood onset, steroid dependent MCNS and no underlying genetic

184 basis (as determined by clinical whole exome sequencing) who progressed to ESKD requiring
185 kidney transplantation. In keeping with a pathogenic role for anti-nephrin autoantibodies, the
186 patient developed massive proteinuria early post-transplant, that in contrast to CNF^{18,19} was
187 associated with high pre-transplant levels of nephrin autoantibodies (Fig. S13).

188

189 **Discussion**

190 Herein, we describe the discovery of circulating autoantibodies against the extracellular domain
191 of nephrin, the essential constituent of the podocyte SD, in a subset of patients with non-
192 congenital acute nephrotic syndrome. These nephrin autoantibodies are specifically present in
193 MCNS kidney biopsies, forming distinct clusters. Our observations share striking parallels with
194 the autoimmune blistering skin condition pemphigus, in which circulating autoantibodies target
195 the desmosomal cell adhesion molecules desmogleins (dsg)²². In pemphigus, these
196 autoantibodies directly interfere with cell adhesion through redistribution, clustering and
197 endocytosis of dsg that disrupts the integrity of the desmosome²². Previous reports of
198 experimental anti-nephrin antibody mediated disruption of nephrin homophilic interactions
199 further support this potential mechanism in MCNS³. Furthermore, pemphigus exhibits a rapid
200 response to glucocorticoid treatment (within days to weeks) that cannot be explained by reduced
201 IgG synthesis alone and may be due to compensatory desmoglein synthesis in keratinocytes²⁵.
202 Similarly, most cases of MCNS respond rapidly to glucocorticoids (within weeks) which have
203 also been shown to upregulate nephrin cell surface expression in cultured human podocytes²⁶.
204 Based on these findings, we speculate that the IgG co-localizing with nephrin in MCNS kidney
205 biopsies may represent *in situ* binding of nephrin autoantibodies. This binding may trigger the
206 redistribution of nephrin and result in SD failure with acute onset, massive proteinuria.

207

208 Recurrent acute nephrotic syndrome in the allograft, referred to as “recurrent FSGS” (rFSGS) in
209 patients with a history of acute nephrotic syndrome in the native kidney, is morphologically
210 indistinguishable from MCNS. Therefore, we also included a study in a transplant patient with an
211 initial diagnosis of MCD in the native kidney which then progressed to FSGS and eventually
212 ESKD. This patient rapidly developed acute and high proteinuria post-transplant consistent with
213 rFSGS, which was not confirmed by a biopsy; however, the pre-transplant serum showed high
214 levels of anti-nephrin antibodies which decreased after aggressive and successful treatment with
215 rituximab and plasmapheresis; this patient went into sustained remission and retained the
216 transplant. We realize that without further corroboration in a larger rFSGS patient sample, no
217 definitive conclusions can be drawn. However, this case illustrates the need to advocate for a
218 comprehensive analysis of anti-nephrin antibodies also in this group of patients with a much
219 more devastating prognosis.

220

221 In conclusion, our discovery adds new insights into the etiology of a disease that has been poorly
222 understood for decades. Future studies will be needed to establish the prevalence of this new
223 subset of anti-nephrin antibody positive NS and the prognostic benefit of anti-nephrin antibodies
224 as a novel, minimally invasive biomarker. Nevertheless, our work provides a mechanistic
225 rationale for consideration of B-cell targeted therapy in a subset of NS patients and allows us to
226 molecularly define those patients who stand to benefit most from the development of new,
227 targeted therapeutic strategies for anti-nephrin antibody positive NS.

228

229

230 **Methods**

231 **Clinical samples (Kidney tissue and serum/plasma)**

232 Renal biopsies were independently assessed by collaborating renal pathologists across four
233 institutions: Brigham and Women's Hospital (BWH), Massachusetts General Hospital (MGH),
234 Boston Medical Center (BMC) and the Mayo Clinic. Serum/plasma was obtained from patients
235 attending those institutions as either discarded samples originally collected for clinical analysis
236 (BWH/BMC/Mayo clinic) or archival samples from the Kidney Disease Biobank (courtesy of
237 Dr. Sushrut Waikar, Partners Healthcare, in accordance with Partners Healthcare IRB Approval
238 for patients attending BWH or MGH and were consented for serum/plasma collection at the time
239 of renal biopsy). Histological studies were performed on archival kidney tissue that was received
240 for routine clinical evaluation and included diffuse podocytopathies, other nephrotic conditions,
241 and non-neoplastic renal parenchyma from tumor nephrectomies. Medical record review,
242 histological and serological studies were approved by the respective Institutional Review Boards
243 (IRB) for those institutions. Similarly, sera were obtained from patients with biopsy proven
244 minimal change disease (MCD) from the Nephrotic Syndrome Study Network (NEPTUNE)
245 longitudinal study²³ during active disease and where available, in remission. Healthy control
246 sera were randomly selected from Partners Healthcare Biobank, specifically excluding those
247 subjects with any renal or autoimmune disease. Sera from nephrotic patients were evaluated for
248 anti-hPLA₂R antibodies at the MGH Immunopathology laboratory using a commercial enzyme
249 linked immunosorbent assay (ELISA) and indirect immunofluorescence test (IIFT)
250 (Euroimmun). Samples were coded to preserve patient anonymity.

251

252

253 **Whole genome sequencing of the NEPTUNE cohort**

254 Whole genome sequencing with a goal median depth of 30x was performed using Illumina Hi-
255 seq. A standard pipeline, Gotcloud, was applied for sequence alignment and variant calling^{27,28}.
256 The variant analysis focused on approximately 70 genes implicated in Mendelian NS. To screen
257 pathogenic variants in the 70 previously implicated Mendelian NS genes, we employed a
258 pipeline similar to one that has been previously reported²⁹. The pathogenicity variants were
259 ultimately classified according to ACMG standards and guidelines³⁰.

260

261 **Human glomerular extract**

262 Human glomerular extract (HGE) was prepared as previously described by Beck *et al*³¹. Briefly,
263 glomeruli were isolated from human kidneys deemed non-suitable for transplantation (that had
264 been authorized for use in medical research) obtained from New England Donor Services, by
265 graded sieving followed by isolation of glomerular proteins in RIPA buffer (Boston
266 BioProducts). IgG was pre-cleared from tissue lysate by incubation with Protein G Plus agarose
267 beads (Santa Cruz). Only kidneys with less than 20% global glomerulosclerosis, on routine
268 wedge biopsy, were used for glomerular isolation.

269

270 **Routine renal biopsy processing**

271 After biopsy acquisition, renal cortex was immediately allocated for light (10% neutral-buffered
272 formalin), immunofluorescence (Zeus transport media) and electron microscopy (Karnovsky's
273 fixative) processing. For routine clinical immunofluorescence, 4 µm cryosections were fixed in
274 95% ethanol for 10 minutes and incubated with FITC-conjugated polyclonal rabbit F(ab)₂ anti-
275 human IgG antibody (Dako; F0315) diluted 1:20. FITC-conjugated sheep anti-human IgG1,

276 IgG2, IgG3, IgG4 (Binding Site; AF006, AF007, AF008, AF009, respectively) diluted 1:20 were
277 used for IgG subclass evaluation. Albumin was detected using FITC-conjugated polyclonal
278 rabbit anti-human albumin (Dako; F0117) diluted 1:30. Sections were mounted using Dako
279 fluorescence mounting medium (Dako; S3023) with a #1.5 coverslip. Immunofluorescence
280 images were acquired on an Olympus BX53 microscope with an Olympus DP72 camera at 150
281 ms exposure.

282

283 **Confocal microscopy**

284 For confocal microscopy, 4 μm cryosections of human kidney biopsies were fixed in 95%
285 ethanol for 10 minutes and subsequently blocked for one hour at room temperature (RT) with
286 phosphate buffer saline (PBS) supplemented with 0.2% fish gelatin, 2% bovine serum albumin
287 (BSA) and 2% fetal bovine serum (FBS). All antibodies were diluted in this blocking solution
288 and incubated for one hour at RT. Nephtrin was detected using 1 $\mu\text{g}/\text{ml}$ primary polyclonal sheep
289 anti-human nephtrin (R&D systems; AF4269) followed by a secondary AlexaFluorTM 568-
290 conjugated donkey anti-sheep IgG (Invitrogen; A21099). Synaptopodin was detected using anti-
291 synaptopodin (N-terminus) guinea pig polyclonal antiserum (Progen; GP94-N) diluted 1:1000
292 followed by a secondary AlexaFluorTM 568-conjugated goat anti-guinea pig IgG (Invitrogen;
293 A11075) antibody. Podocin and Wilms Tumor 1 (WT1) were detected using a primary
294 polyclonal rabbit anti-human podocin (Millipore Sigma; P0372) and a primary monoclonal
295 rabbit anti-human WT1 clone SC06-41 (Invitrogen; MA5-32215) diluted 1:500 and 1:300
296 respectively, followed by a secondary AlexaFluorTM 568-conjugated donkey anti-rabbit IgG
297 (Invitrogen; A10042). IgG immune deposits were detected using a primary monoclonal mouse
298 anti-human IgG antibody (Abcam; ab200699) diluted 1:750 followed by a secondary

299 AlexaFluorTM 488-conjugated donkey anti-mouse IgG (Invitrogen; A21202). All secondary
300 AlexaFluorTM-conjugated antibodies were diluted 1:500. Sections were mounted using
301 Vectashield anti-fade mounting medium (Vectashield, H-1000) with a #1.5 coverslip and images
302 were acquired on a Leica TCS SPE microscope.

303

304 **Structured Illumination Microscopy (SIM)**

305 Structured Illumination Microscopy (SIM) imaging was performed on 4 μm fixed, frozen human
306 kidney biopsy sections processed according to the aforementioned protocol for confocal
307 microscopy. All images were collected using an OMX V4 Blaze (GE Healthcare) microscope
308 equipped with three watercooled PCO.edge sCMOS cameras, 488 nm, 568 nm laser lines, and
309 528/48 nm, 609/37 nm emission filters (Omega Optical). Images were acquired with a 60X/1.42
310 Plan-Apochromat objective lens (Olympus) with a final pixel size of 80 nm. Z stacks of 4-8 μm ,
311 were acquired with a 0.125 μm z-spacing, and 15 raw images (three rotations with five phases
312 each) were acquired per plane. Spherical aberration was minimized for each sample using
313 immersion oil matching²⁴. Super resolution images were computationally reconstructed from the
314 raw data sets with a channel-specific, measured optical transfer function, and a Wiener filter
315 constant of 0.001 using CUDA-accelerated 3D-SIM reconstruction code³². Axial and lateral
316 chromatic misregistration was determined using a single biological calculation slide, prepared
317 with human kidney tissue stained with a primary mouse anti-human IgG monoclonal antibody
318 (Abcam; ab200699) followed by both secondary AlexaFluorTM 488-conjugated donkey anti-
319 mouse IgG (Invitrogen; A21202) and AlexaFluorTM 568-conjugated goat anti-mouse IgG
320 (Invitrogen; A11031) antibodies on the same tissue cryosection. Experimental data sets were
321 then registered using the imwarp function in MATLAB (MathWorks)³³.

322

323

324 **Generation of recombinant human nephrin and phospholipase A₂ receptor (PLA₂R)**

325 Separate plasmids encoding the extracellular subdomains of human nephrin (amino acids 1-
326 1059), comprising the 8 Ig-like C2-type domains and a single fibronectin type III domain, and
327 human phospholipase A₂ receptor (hPLA₂R), comprising the N-terminal ricin domain,
328 fibronectin type II domain and 8 C-type lectin domains (CTLD), both with C-terminal
329 polyhistidine (6XHIS) tags, were generated by standard cloning techniques. The correct
330 sequences were confirmed by whole plasmid sequencing (MGH DNA core). HEK293-F cells
331 (Thermo Fisher) were transfected with 0.5 µg plasmid per 10⁶ cells using 1.5 µg PEI
332 (polyethylenimine). The plasmid and PEI were pre-incubated for 20 mins in Freestyle media
333 (Thermo Fisher) at one tenth the final volume and then added dropwise to the cells. After 3-5
334 days, provided the cell viability was >95%, the cell culture media was harvested by
335 centrifugation (300 xg for 10 mins). Imidazole was added to a final concentration of 10 mM and
336 the media was filter sterilized (0.2 µm) on ice. Nickel NTA resin (Qiagen) was washed 3x with
337 10 mM Imidazole in PBS and then incubated with the filtered media overnight at 4°C on a roller
338 mixer (Thermo Fisher). The Nickel NTA resin was then washed 3x with 10 mM Imidazole in
339 PBS and the recombinant proteins were eluted with 300 mM Imidazole in PBS. The purity of the
340 eluted fractions was confirmed by SDS-PAGE with a 4-12% Bis-Tris gel (Invitrogen), pooled
341 together and concentrated to 1 ml using an Amnicon centrifugation filter with a 10K molecular
342 weight cut off (Millipore). The resultant protein was run over a SephadexTM 300 column and 0.5
343 ml fractions were collected. The purity of the eluted fractions was confirmed by SDS-PAGE on a
344 4-12% Bis-Tris gel (Invitrogen) and the concentration determined by measuring absorbance at

345 280 nm using a Nanodrop spectrophotometer (Thermo Fisher). Immunoreactivity of the purified
346 nephrin was confirmed by Western blot analysis, under reducing conditions using a primary
347 sheep anti-human nephrin antibody (R&D) followed by a secondary HRP-conjugated donkey
348 anti-sheep IgG antibody (Jackson immunoresearch), and of the purified hPLA₂R under non-
349 reducing conditions using serum from a patient with known anti-PLA₂R antibodies (determined
350 by commercial ELISA and IIFT (Euroimmun)) diluted 1:1000 and a secondary HRP-conjugated
351 donkey anti-human IgG antibody (Jackson Immunoresearch).

352

353 **Enzyme Linked Immunosorbent Assay (ELISA)**

354 Please contact the corresponding author for information.

355

356 **Immunoprecipitation and Western Blot**

357 Please contact the corresponding author for information.

358

359 **Acknowledgements**

360 We acknowledge Lin Shao (Yale University) for CUDA-accelerated 3D-SIM reconstruction
361 code, and Talley Lambert, Anna Payne-Jost and Jennifer Waters (Nikon Imaging Core, Harvard
362 Medical School) for assistance with SIM acquisition. We are grateful to Dr. Opeyemi Olabisi for
363 ApoL1 genotyping, and Drs. Emily Dulude, Durga Rao and Andrew Bentall for providing
364 supporting clinical data. We are thankful to Dr. Colin Garvie and Dr. Kasia Handing for
365 assistance with protein purification. We thank Terri Woo, Colleen Ford, Kristie Swett, Hui Chen
366 and Brant Douglas for expert technical assistance, and Dr. Andrew Lichtman, Dr. David Salant,
367 Dr. Moran Dvela, Dr. Juanchi Pablo, Dr. Silvana Bazua Valenti, Dr. Katherine Vernon, Dr.

368 Valeria Padovano and Morgan Thompson for enlightening discussions. We thank Dr. Camden
369 Bay from Harvard Catalyst for biostatistics consultation. A.J.B.W. was supported by T32
370 training fellowships T32HL007627 and T32DK007527. A.W. was supported by an Eleanor
371 Miles Shore Fellowship by Harvard Medical School and is a current recipient of a
372 NephCure/NEPTUNE ancillary study award. G.L. is supported by NIH grant DK007053-45S1.
373 A.G. is supported by NIH grants DK099465 and DK095045. S.W. is supported by NIH grants
374 U01DK085660, U01DK104308, and UG3DK114915. M.S. is supported by NIH grant
375 R01DK119380 and R01DK1088085. A.G. has financial interest in Goldfinch Biopharma, which
376 was reviewed and is managed by Brigham and Women’s Hospital, Mass General Brigham, the
377 Broad Institute and Harvard University in accordance with their conflict of interest policies.
378 A.J.B.W., K.H.K., A.W., J.M.H and H.G.R. have filed a provisional patent “Methods for
379 identifying and treating patients with antibody-mediated acquired primary or recurrent idiopathic
380 nephrotic syndrome”. The Nephrotic Syndrome Study Network Consortium (NEPTUNE), U54-
381 DK-083912, is a part of the National Institutes of Health (NIH) Rare Disease Clinical Research
382 Network (RDCRN), supported through a collaboration between the Office of Rare Diseases
383 Research (ORDR), NCATS, and the National Institute of Diabetes, Digestive, and Kidney
384 Diseases. Additional funding and/or programmatic support for this project has also been
385 provided by the University of Michigan, the NephCure Kidney International and the Halpin
386 Foundation.
387

388 References

- 389 1. Vivarelli, M., Massella, L., Ruggiero, B. & Emma, F. Minimal Change Disease. *Clin J*
390 *Am Soc Nephrol* **12**, 332-345 (2017).
- 391 2. Grahammer, F., Schell, C. & Huber, T.B. The podocyte slit diaphragm--from a thin grey
392 line to a complex signalling hub. *Nat Rev Nephrol* **9**, 587-598 (2013).
- 393 3. Khoshnoodi, J., *et al.* Nephrin promotes cell-cell adhesion through homophilic
394 interactions. *Am J Pathol* **163**, 2337-2346 (2003).
- 395 4. Kestila, M., *et al.* Positionally cloned gene for a novel glomerular protein--nephrin--is
396 mutated in congenital nephrotic syndrome. *Mol Cell* **1**, 575-582 (1998).
- 397 5. Liu, L., *et al.* Defective nephrin trafficking caused by missense mutations in the NPHS1
398 gene: insight into the mechanisms of congenital nephrotic syndrome. *Hum Mol Genet* **10**,
399 2637-2644 (2001).
- 400 6. Elie, V., Fakhoury, M., Deschenes, G. & Jacqz-Aigrain, E. Physiopathology of idiopathic
401 nephrotic syndrome: lessons from glucocorticoids and epigenetic perspectives. *Pediatr*
402 *Nephrol* **27**, 1249-1256 (2012).
- 403 7. Coward, R.J., *et al.* Nephrotic plasma alters slit diaphragm-dependent signaling and
404 translocates nephrin, Podocin, and CD2 associated protein in cultured human podocytes.
405 *J Am Soc Nephrol* **16**, 629-637 (2005).
- 406 8. Ravani, P., Bertelli, E., Gill, S. & Ghiggeri, G.M. Clinical trials in minimal change
407 disease. *Nephrol Dial Transplant* **32**, i7-i13 (2017).
- 408 9. Ravani, P., Bonanni, A., Rossi, R., Caridi, G. & Ghiggeri, G.M. Anti-CD20 Antibodies
409 for Idiopathic Nephrotic Syndrome in Children. *Clin J Am Soc Nephrol* **11**, 710-720
410 (2016).
- 411 10. Basu, B., *et al.* Efficacy of Rituximab vs Tacrolimus in Pediatric Corticosteroid-
412 Dependent Nephrotic Syndrome: A Randomized Clinical Trial. *JAMA Pediatr* **172**, 757-
413 764 (2018).
- 414 11. Basu, B. Ofatumumab for rituximab-resistant nephrotic syndrome. *N Engl J Med* **370**,
415 1268-1270 (2014).
- 416 12. Fenoglio, R., *et al.* Rituximab as a front-line therapy for adult-onset minimal change
417 disease with nephrotic syndrome. *Oncotarget* **9**, 28799-28804 (2018).
- 418 13. Madanchi, N., Bitzan, M. & Takano, T. Rituximab in Minimal Change Disease:
419 Mechanisms of Action and Hypotheses for Future Studies. *Can J Kidney Health Dis* **4**,
420 2054358117698667 (2017).
- 421 14. D'Agati, V.D. Minimal Change Disease. in *Atlas of Nontumor Pathology. Non-neoplastic*
422 *Kidney Kidney Diseases.*, Vol. Fascicle 4 109 (American Registry of Pathology,
423 Washington, DC, 2005).
- 424 15. Oriksa, M., Matsui, K., Oite, T. & Shimizu, F. Massive proteinuria induced in rats by a
425 single intravenous injection of a monoclonal antibody. *J Immunol* **141**, 807-814 (1988).
- 426 16. Topham, P.S., *et al.* Nephritogenic mAb 5-1-6 is directed at the extracellular domain of
427 rat nephrin. *J Clin Invest* **104**, 1559-1566 (1999).
- 428 17. Takeuchi, K., *et al.* New Anti-Nephrin Antibody Mediated Podocyte Injury Model Using
429 a C57BL/6 Mouse Strain. *Nephron* **138**, 71-87 (2018).
- 430 18. Holmberg, C. & Jalanko, H. Congenital nephrotic syndrome and recurrence of
431 proteinuria after renal transplantation. *Pediatr Nephrol* **29**, 2309-2317 (2014).

- 432 19. Kuusniemi, A.M., *et al.* Plasma exchange and retransplantation in recurrent nephrosis of
433 patients with congenital nephrotic syndrome of the Finnish type (NPHS1).
434 *Transplantation* **83**, 1316-1323 (2007).
- 435 20. Doublier, S., *et al.* Nephtrin redistribution on podocytes is a potential mechanism for
436 proteinuria in patients with primary acquired nephrotic syndrome. *Am J Pathol* **158**,
437 1723-1731 (2001).
- 438 21. Wernerson, A., *et al.* Altered ultrastructural distribution of nephtrin in minimal change
439 nephrotic syndrome. *Nephrol Dial Transplant* **18**, 70-76 (2003).
- 440 22. Hammers, C.M. & Stanley, J.R. Mechanisms of Disease: Pemphigus and Bullous
441 Pemphigoid. *Annu Rev Pathol* **11**, 175-197 (2016).
- 442 23. Gadegbeku, C.A., *et al.* Design of the Nephrotic Syndrome Study Network (NEPTUNE)
443 to evaluate primary glomerular nephropathy by a multidisciplinary approach. *Kidney Int*
444 **83**, 749-756 (2013).
- 445 24. Gustafsson, M.G. Surpassing the lateral resolution limit by a factor of two using
446 structured illumination microscopy. *J Microsc* **198**, 82-87 (2000).
- 447 25. Nguyen, V.T., *et al.* Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal
448 effects on keratinocytes. *J Biol Chem* **279**, 2135-2146 (2004).
- 449 26. Xing, C.Y., *et al.* Direct effects of dexamethasone on human podocytes. *Kidney Int* **70**,
450 1038-1045 (2006).
- 451 27. Jun, G., Wing, M.K., Abecasis, G.R. & Kang, H.M. An efficient and scalable analysis
452 framework for variant extraction and refinement from population-scale DNA sequence
453 data. *Genome Res* **25**, 918-925 (2015).
- 454 28. Gillies, C.E., *et al.* An eQTL Landscape of Kidney Tissue in Human Nephrotic
455 Syndrome. *Am J Hum Genet* **103**, 232-244 (2018).
- 456 29. Sampson, M.G., *et al.* Using Population Genetics to Interrogate the Monogenic Nephrotic
457 Syndrome Diagnosis in a Case Cohort. *J Am Soc Nephrol* **27**, 1970-1983 (2016).
- 458 30. Richards, S., *et al.* Standards and guidelines for the interpretation of sequence variants: a
459 joint consensus recommendation of the American College of Medical Genetics and
460 Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405-424 (2015).
- 461 31. Beck, L.H., Jr., *et al.* M-type phospholipase A2 receptor as target antigen in idiopathic
462 membranous nephropathy. *N Engl J Med* **361**, 11-21 (2009).
- 463 32. Hiraoka, Y., Sedat, J.W. & Agard, D.A. Determination of three-dimensional imaging
464 properties of a light microscope system. Partial confocal behavior in epifluorescence
465 microscopy. *Biophys J* **57**, 325-333 (1990).
- 466 33. Matsuda, A., Schermelleh, L., Hirano, Y., Haraguchi, T. & Hiraoka, Y. Accurate and
467 fiducial-marker-free correction for three-dimensional chromatic shift in biological
468 fluorescence microscopy. *Sci Rep* **8**, 7583 (2018).

469




Figure 1

Figure 1: Circulating autoantibodies against nephrin are present in a subset of MCD patients from the NEPTUNE study cohort and correlate with disease activity.

(a) Antibodies against the extracellular domain of recombinant human nephrin (hNephrin_{G1059}) were measured by indirect ELISA. Antigen specific binding was determined by subtracting the average OD_{450nm} of duplicate uncoated wells (nonspecific background) from the average OD_{450nm} of duplicate hNephrin_{G1059} coated wells for each individual patient sample. A relative antibody titer was then determined from a standard curve that was generated using a single positive patient sample with a 1:100 dilution defined as containing 1000 Units/ml. The threshold for anti-nephrin antibody positivity (187 Units/ml) was defined as the maximum antibody titer, as the cohort was not normally distributed, in a healthy control population (n=30) with no known kidney disease (dotted line) to maximize specificity. The earliest serum sample available during active disease (urine protein creatinine ratio (UPCR) > 3 g/g on the day of sample collection) was positive for anti-nephrin antibodies in 18 (29%) of 62 patients with biopsy proven MCD from the NEPTUNE cohort. 53 (98%) of 54 nephrotic control patients with anti-human phospholipase A₂ receptor (hPLA₂R+) antibodies, as determined by clinical ELISA and IIFT assays (Euroimmun), were negative for anti-nephrin antibodies. The intra and inter-assay coefficient of variances for the anti-nephrin antibody ELISA were 5.56% and 14.36% respectively. The antibody titer for the NEPTUNE patients and controls are given in Supplemental Table S1. **(b)** 11 of the 18 NEPTUNE patients who were anti-nephrin antibody positive during active disease (blue bar) had a subsequent serum sample available during complete remission (UPCR < 0.3 g/g on the day of sample collection) which tested anti-nephrin antibody negative (red bar) in all cases. Dotted line indicates threshold for positive antibody titer (187 Units/ml). Student t-test was used to compare differences between the active and remission samples **p<0.01, ***p<0.001. **(c)** The same serum samples

evaluated by ELISA from the NEPTUNE cohort (b) were evaluated for their ability to immunoprecipitate nephrin from HGE (derived from non-diseased human kidney). In keeping with the ELISA results, only serum obtained during active disease (indicated by an arrow with an A (blue colored) above it) immunoprecipitated nephrin, whereas serum obtained during remission (indicated by an arrow with a R (red colored) above it) did not. Total IgG was comparable between active and remission samples for each patient.









Figure 2

Figure 2: Renal biopsy imaging studies and serological testing for anti-nephrin antibodies in patients with biopsy proven MCD

(a) Representative confocal microscopy images of glomeruli in IgG-positive MCD (MCD1+/MCD7+) and IgG-negative MCD (MCD5-), stained for IgG (green) and the podocyte slit-diaphragm protein nephrin (red). There is a clear overlap (yellow) between IgG (green) and nephrin (red) specifically with the punctate IgG and not background as seen in the MCD+ biopsies (MCD1+/MCD7+) (white arrows) but not in MCD- biopsies. The right panels show magnified images of boxed areas of MCD1+ and MCD7+ biopsies. Scale bar: 10 μ m. **(b)** Representative confocal microscopy images of glomeruli in IgG-positive MCD (MCD1+/MCD7+) and IgG-negative MCD (MCD5-), stained for punctate IgG (green) (indicated with white arrow) and the cytoskeletal podocyte marker synaptopodin (red). There is no appreciable overlap between IgG and Synaptopodin in any of those cases. The right panels show magnified images of boxed areas of MCD1+ and MCD7+ biopsies. Scale bar: 10 μ m. **(c)** Super Resolution Structured Illumination Microscopy (SIM) images of 0.125 μ m individual Z-slices showing *en face* views of the podocyte junction from a representative renal biopsy (MCD1+) in which the nephrin remains GBM-associated, forming a curvilinear pattern. The left image shows co-localization (yellow) of IgG (green) with the slit diaphragm protein nephrin (red), in contrast to mutual exclusivity with the foot process associated synaptopodin (red) shown in the right image, indicating intimate spatial association with nephrin along the podocyte slit diaphragm. (Full image stack shown in Figure S8). Scale bar: 1 μ m. **(d)** SIM image of 0.125 μ m individual Z-slices from a representative renal biopsy (patient MCD7+) in which nephrin is redistributed to a more granular pattern. The left image shows co-localization (yellow) of IgG (green) with the slit diaphragm protein nephrin (red), in contrast to mutual exclusivity with the foot process associated synaptopodin (red) shown in the

right image, indicating a continued close spatial association of the IgG with the redistributed nephrin. (Full image stack shown in supplemental Figure S8). Scale bar: 1 μ m. **(e)** All of the patients with MCD and IgG deposition on biopsy (n=9) were anti-nephrin antibody positive, whereas all of the control subjects lacking IgG deposition on biopsy, consisting of DN (n=2), Amyloidosis (n=1), IgG-negative FSGS (n=2), IgG-negative TL (n=1), normal (n=1), disease-free region of tumor nephrectomy (n=2) and IgG-negative MCD (n=3), were anti-nephrin antibody negative (n=12). The Mann-Whitney U test was used to compare differences between the groups ***p<0.001. **(f)** Serum/plasma samples were obtained from patients with biopsy proven IgG-positive MCD (MCD+) during active disease (within 7 days of presentation with NS) and follow-up samples were obtained during complete (MCD4+, MCD7+) or partial (MCD8+) remission on the day of sample collection. For MCD3+, the follow-up serum sample was obtained approximately 3 weeks after entering a period of sustained complete remission. The threshold for a positive anti-nephrin antibody titer of 187 U/ml (indicated by dotted line) was based on the upper limit of a healthy control population. Anti-nephrin antibodies in serum/plasma were undetectable or significantly reduced to below the threshold for positivity, (red bar) during clinical remission compared with those during active disease (blue bar). Complete remission was defined as urinary protein creatinine ratio (UPCR) < 0.3 g/g or urinary albumin creatinine ratio (UACR) < 0.2 g/g. Partial remission was defined as a > 50% reduction in proteinuria (UPCR) that did not fall below 0.3 g/g. Student t-test was used to compare differences between the active and remission samples **p<0.01, ***p<0.001.